Patrick Caron

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2645827/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Liquid chromatography coupled to tandem mass spectrometry methods for the selective and sensitive determination of 24Sâ€hydroxycholesterol, its sulfate, and/or glucuronide conjugates in plasma. Journal of Mass Spectrometry, 2022, 57, e4827.	1.6	2
2	Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT). Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0
3	A liquid chromatography-mass spectrometry assay for the quantification of nucleotide sugars in human plasma and urine specimens and its clinical application. Journal of Chromatography A, 2022, 1677, 463296.	3.7	3
4	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica, 2021, 106, 2251-2256.	3.5	7
5	Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. British Journal of Cancer, 2021, 125, 78-84.	6.4	5
6	Circulating Levels of Sex Steroid Hormones and Gastric Cancer. Archives of Medical Research, 2021, 52, 660-664.	3.3	8
7	A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry. Journal of Chromatography A, 2021, 1650, 462228.	3.7	15
8	Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women. Hepatology, 2020, 72, 535-547.	7.3	23
9	UGT2B17 modifies drug response in chronic lymphocytic leukaemia. British Journal of Cancer, 2020, 123, 240-251.	6.4	13
10	Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation. Drug Metabolism and Disposition, 2020, 48, 75-84.	3.3	10
11	Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. British Journal of Cancer, 2020, 122, 1068-1076.	6.4	13
12	Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. Journal of Urology, 2020, 203, 940-948.	0.4	8
13	Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy Journal of Clinical Oncology, 2020, 38, 148-148.	1.6	0
14	Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men. Journal of the National Cancer Institute, 2019, 111, 34-41.	6.3	42
15	Inactivation of Prostaglandin E2 as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2019, 9, 606.	2.8	12
16	Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody. Drug Metabolism and Disposition, 2019, 47, 444-452.	3.3	8
17	A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 701-706.	2.5	13
18	An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1104, 249-255.	2.3	13

PATRICK CARON

#	Article	IF	CITATIONS
19	Estradiol metabolites as biomarkers of endometrial cancer prognosis after surgery. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 45-54.	2.5	15
20	Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients. Annals of Hematology, 2018, 97, 1649-1661.	1.8	12
21	Urinary Elimination of Bile Acid Glucuronides under Severe Cholestatic Situations: Contribution of Hepatic and Renal Glucuronidation Reactions. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-12.	1.9	12
22	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A <i>Post Hoc</i> Analysis of the PR.7 Trial. Clinical Cancer Research, 2018, 24, 5305-5312.	7.0	13
23	Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR Study. PLoS ONE, 2018, 13, e0190325.	2.5	38
24	The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. European Urology, 2016, 69, 601-609.	1.9	36
25	The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy. Endocrine-Related Cancer, 2015, 22, 77-85.	3.1	9
26	Quantitative Profiling of Human Renal UDP-glucuronosyltransferases and Glucuronidation Activity: A Comparison of Normal and Tumoral Kidney Tissues. Drug Metabolism and Disposition, 2015, 43, 611-619.	3.3	79
27	Association Between Circulating Levels of Sex Steroid Hormones and Barrett's Esophagus in Men: A Case–Control Analysis. Clinical Gastroenterology and Hepatology, 2015, 13, 673-682.	4.4	30
28	A chromatography/tandem mass spectrometry method for the simultaneous profiling of ten endogenous steroids, including progesterone, adrenal precursors, androgens and estrogens, using low serum volume. Steroids, 2015, 104, 16-24.	1.8	51
29	Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential. Drug Metabolism and Disposition, 2015, 43, 1331-1335.	3.3	39
30	Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway. Clinical Cancer Research, 2014, 20, 2971-2983.	7.0	27
31	Enzymatic Production of Bile Acid Glucuronides Used as Analytical Standards for Liquid Chromatographyâ ``Mass Spectrometry Analyses. Molecular Pharmaceutics, 2006, 3, 293-302.	4.6	23